Nanjing Leads Biolabs sets up Phase 1 safety readout for dual-target lupus drug LBL-047
The first human data on a bifunctional BDCA2/BAFF-APRIL fusion protein will test tolerability, not efficacy, in healthy volunteers before the drug advances to lupus patients.
Executive Summary
- A first-in-human safety study is approaching a data readout that will decide whether a dual-mechanism lupus candidate can proceed into the patient population it was designed for.
- The primary endpoint measures adverse events in healthy volunteers, not disease activity, so the readout speaks to tolerability rather than clinical benefit.
- The molecule combines two mechanisms that each have later-stage precedent individually, but no registered competitor pairs them, leaving this program without a direct comparator in human testing.
- The sponsor has held its guided readout window unchanged across five public disclosures over eight months, a pattern of stable communication rather than drift.
The trial
LBL-047, known outside China as DNTH212, is being tested in a two-part Phase 1 study registered as NCT07323173: Part A enrolls healthy adults, and Part B enrolls patients with mild to moderate systemic lupus erythematosus (SLEDAI-2K score of 4 to 10 at screening). The trial targets 112 participants, started December 16, 2025, and carries a primary completion date of December 16, 2027. The primary endpoint is the occurrence of treatment-emergent and serious adverse events, a safety and tolerability measure rather than an efficacy readout. Secondary endpoints cover pharmacodynamics, maximum concentration, time to maximum concentration, and immunogenicity. NCT07323173A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus ErythematosusNCT07323173
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the readout can establish
Because Part A enrolls healthy volunteers rather than lupus patients, the H2-2026 data can only speak to how the drug behaves in the body and whether it is tolerated at the doses tested; it cannot demonstrate disease-modifying effect. That is the intended sequence for a first-in-human study: establish an acceptable safety profile in healthy adults, then carry the regimen into Part B's lupus patients. The trial is not registrational, so this readout functions as a gate to the next development step rather than a standalone regulatory catalyst. NCT07323173A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus ErythematosusNCT07323173
The mechanism
DNTH212 is designed as a bifunctional fusion protein that targets BDCA2 on plasmacytoid dendritic cells, intended to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B-cell activity. Dianthus Therapeutics, which licensed the molecule from Leads Biolabs in October 2025, has said the compound showed pDC depletion in vitro compared with litifilimab, a BDCA2-targeting antibody, and immunoglobulin reduction in non-human primates compared with povetacicept, a BAFF/APRIL inhibitor. Those are preclinical and cross-species comparisons, not clinical trial results, and this Phase 1 study is the first human test of the combined mechanism. DianthusDianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a ...Oct 16, 2025
Competitive field
The systemic lupus erythematosus field carries active Phase 3 programs targeting single mechanisms individually, including BDCA2 (litifilimab, Biogen), BAFF (belimumab, tested across multiple sponsors), and IFNAR1 (anifrolumab, AstraZeneca), among others. None of the registered comparators pair BDCA2 and BAFF/APRIL inhibition in a single molecule, so LBL-047 has no direct mechanism-matched precedent to benchmark against in this indication. That leaves the healthy-volunteer safety data as the first real-world signal for whether combining two validated single-target mechanisms compounds tolerability risk beyond what each mechanism shows on its own.
Timing track record
The sponsor and its licensing partner have disclosed the same H2-2026 guidance window in five separate communications dated October 16, 2025, November 5, 2025, December 23, 2025, May 5, 2026, and May 6, 2026, with no change to the stated start or end dates. The trial's protocol has recorded no primary completion date changes, no endpoint amendments, and no eligibility criteria changes since its first registry posting on January 7, 2026. That consistency across both public guidance and registry data points to an execution-stable program heading into its readout window. NCT07323173A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus ErythematosusNCT07323173
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.